A practical reference on thymosin alpha 1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-03. Anything still debated is marked as such rather than presented as settled.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| 化学分类 | 线性肽 | 由28个氨基酸组成 |
| 分子量 | 约3108 Da | 合成版本一致 |
| 外观 | 白色至类白色粉末 | 冻干品 |
| 溶解度 | 易溶于水 | 微溶于有机溶剂 |
| 储存温度 | -20°C（冻干） | 溶解后2-8°C |
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
== History == The concept was first established in the late eighties by Dr. Michael D. West. Dr. West has, through collaboration with Geron, Inc. later funded work in Judith Campisi's lab to create a cell-based screen for drugs that inhibit the phenotype. Campisi subsequently named the phenotype SASP.
Neanderthal specimens vary in height from 147.5 to 177 cm (4 ft 10 in to 5 ft 10 in), with average male dimensions estimated at 165 cm (5 ft 5 in) and 75 kg (165 lb). While Neanderthal brain volume and ratio to body size averaged higher than any living human population — 1,640 cc (100 cu in) for males and 1,460 cc (89 cu in) for females — their brain organisation differed from modern humans in areas related to cognition and language, which could explain the comparative simplicity of Neanderthal behaviour to Cro-Magnons in the archaeological record. Neanderthals maintained a low population and suffered inbreeding depression, which may have impeded their ability to progress technologically. They produced Mousterian stone tools (a Middle Palaeolithic industry) and possibly wore blankets and ponchos. They maintained and might have created fire. They predominantly ate whatever was abundant close to home, usually big game as well as plants and mushrooms. Neanderthals were frequently victims of major physical traumas and animal attacks. Examples of Palaeolithic art have been inconclusively attributed to Neanderthals, namely possible ornaments made from bird claws and feathers; collections of unusual objects including crystals and fossils; and engravings. Neanderthals buried their dead, but there is no clear indication that they believed in life after death.
=== Euphemisms === A huge variety of euphemisms and dysphemisms have been invented to describe semen (for a list of terms see: Sexual slang). Slang terms for semen include cum, jism (also shortened to jizz), spunk (primarily British English), spooge, splooge, load, nut, seed, and love juice. The term cum can also refer to an orgasm (when used as a verb rather than as a noun). The term nut originally referred to a testicle, but can be used to refer to both semen and ejaculation.
Sources: en.wikipedia.org
The Kuwaiti oil fires were caused by the Iraqi military setting fire to 700 oil wells as part of a scorched earth policy while retreating from Kuwait in 1991 after conquering the country but being driven out by coalition forces. The fires started in January and February 1991, and the last one was extinguished by November. The resulting fires burned uncontrollably because of the dangers of sending in firefighting crews. Land mines had been placed in areas around the oil wells, and a military cleaning of the areas was necessary before the fires could be put out. Somewhere around 6 million barrels (950,000 m3) of oil were lost each day. Eventually, privately contracted crews extinguished the fires, at a total cost of US$1.5 billion to Kuwait. By that time, however, the fires had burned for approximately 10 months, causing widespread pollution.
Distribution of the Asian citrus psyllid is primarily in tropical and subtropical Asia. It has been reported in all citrus-growing regions in Asia except mainland Japan. The disease has affected crops in China, India, Sri Lanka, Malaysia, Indonesia, Myanmar, the Philippines, Pakistan, Thailand, the Ryukyu Islands, Nepal, Saudi Arabia, and Afghanistan. Areas outside Asia have also reported the disease: Réunion, Mauritius, Brazil, Paraguay, Florida since 2005, and in several municipalities in Mexico since 2009. On 30 March 2012, citrus greening disease was confirmed in a single citrus tree in California. The first report of HLB in Texas occurred on 13 January 2012, from a Valencia sweet orange tree in a commercial orchard in Texas. Prospects are bleak for the ubiquitous backyard citrus orchards of California as residential growers are unlikely to consistently use the pesticides which provide effective control in commercial orchards. The distribution of the African citrus psyllid includes Africa, Madeira, Saudi Arabia, Portugal, and Yemen. This species is sensitive to high temperatures and will not develop at temperatures greater than 25 °C (77 °F). It is a vector of the African strain of huanglongbing (Candidatus Liberibacter africanus), which is sensitive to heat. This strain is reported to occur in Africa, (Burundi, Cameroon, Central African Republic, Comoros, Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Reunion, Rwanda, South Africa, St. Helena [unconfirmed], Swaziland, Tanzania, Zimbabwe), Saudi Arabia, and Yemen. The disease was not reported in the EU as of 2004.
==== Harris lines ==== Harris lines form before adulthood, when bone growth is temporarily halted or slowed down due to some sort of stress (typically disease or malnutrition). During this time, bone mineralization continues, but growth does not, or does so at reduced levels. If and when the stressor is overcome, bone growth resumes, resulting in a line of increased mineral density visible in a radiograph. Absent removal of the stressor, no line forms. Particularly, deficiencies in protein and vitamins, which lead to delayed longitudinal bone growth, can result in the formation of Harris lines. During the process of endochondral bone growth, the cessation of osteoblastic activity results in the deposition of a thin layer of bone beneath the cartilage cap, potentially forming Harris lines. Subsequent recovery, necessary for the restoration of osteoblastic activity, is also implicated in Harris line formation. When matured cartilage cells reactivate, bone growth resumes, thickening the bony stratum. Therefore, complete recovery from periods of chronic illness or malnutrition manifests as transverse lines on radiographs. Lines tend to be thicker with prolonged and severe malnutrition. Harris line formation typically peaks in long bones around 2–3 years after birth and becomes rare after the age of 5 until adulthood. Harris lines occur more frequently in boys than in girls.
Sources: en.wikipedia.org
In spite of 2018 election promises that "not a single person will lose their job" under his PC government, Ontario Health Minister Christine Elliot office announced in June 2019 that 416 workers would be laid off, as 20 health agencies, including 14 local health integration networks (LHINs), Cancer Care Ontario, eHealth Ontario were merged into one new super-agency called Ontario Health. With the merger "another 409 vacant positions will be eliminated." These changes are estimated to save "$350 million a year by 2021–22". A CBC News report said that the average wait times in Ontario hospitals set a new June record of an average of 16.3 hours waiting in emergency rooms in 2019, compared to 14.4 hours in June 2018, based on Health Quality Ontario data. More restructuring was announced by the Health ministry in September and no more job losses are anticipated. On November 18, 2024, Ford's government tabled a bill to ban supervised injection sites from operating within 200 meters of a school or child-care centre. The bill would also require municipalities to get approval from the provincial health minister and federal government before launching new facilities. In a news conference for the bill, Health Minister Sylvia Jones stated, "I want to be very clear, there will be no further safe injection sites in the province of Ontario under our government."
== LED light therapy v.s laser therapy == In the field of phototherapy, Low-Level Laser Therapy (LLLT) and LED Therapy (LEDT) are well-known modalities that provide non-invasive treatment options for a variety of medical conditions. Low-Level Laser Therapy (LLLT) employs low-intensity lasers, occasionally supplemented by LED lighting, to address a variety of medical conditions. Similar to LED Therapy (LEDT), LLLT's applications include the treatment of skin issues such as inflammation and pigmentation, tissue damage, and cardiovascular concerns. Although both LEDT and LLLT share therapeutic goals, LEDT is particularly noted for its cost-effectiveness and is designed for broader coverage using expansive LED panels, whereas LLLT utilizes more focused, coherent laser light for targeted areas. For this reason, laser therapy is appropriate for treating tissues beneath the hypodermis, LED therapy is more effective in treating cutaneous diseases.
This standard was written for a biological manufacturing company and was then written into the PDA's Technical Report # 39, thus establishing the industry standard for cold chain validation. This was critical for the industry due to the sensitivity of drug substances, biologics and vaccines to various temperature conditions. The FDA has also been very focused on this final area of distribution and the potential for a drug substances quality to be impacted by extreme temperature exposure. 4.6. Accuracy: Accuracy of an analytical procedure is the closeness of test results obtained by that procedure to the true value. The accuracy of an analytical procedure shall be established across its range. 4.7. Precision: The precision of an analytical procedure expresses the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. 4.8. Method precision (Repeatability): Method precision carried out on different test preparation of a homogenous sample within short interval of time under same experimental conditions. 4.9. Intermediate precision (Ruggedness): Intermediate precision (Ruggedness) expresses within-laboratories variations i.e. different days, different analysts, different equipment etc. 4.10. Range: The range of an analytical procedure is the interval between the upper and lower concentration of analyte in the sample for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity
=== Interests === Freeman resides in Charleston, Mississippi, and maintains a home in New York City. He earned a private pilot's license at the age of 65 and owns—or has owned—at least three private aircraft, including both a Cessna Citation 501 and Cessna 414 as well as an Emivest SJ30. In December 2010, Freeman joined former President Bill Clinton, president of the United States Soccer Federation Sunil Gulati, and soccer player Landon Donovan in Zurich for a presentation to bid for the U.S. hosting rights for the 2022 FIFA World Cup. Freeman's favorite film that he did not work on is Moulin Rouge!. He later reaffirmed this during his tribute speech at Nicole Kidman's AFI Life Achievement Award ceremony.
Sources: en.wikipedia.org
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。
天然胸腺素α1主要从胸腺组织提取，也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本，不再依赖动物组织。
胸腺素组分5是牛胸腺提取物的粗组分，包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽，具有明确的28个氨基酸序列。
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.